Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 39.06 kDa 
• Atom Count: 2552 
• Modelled Residue Count: 294 
• Deposited Residue Count: 342 
• Unique protein chains: 1

4ANQ

Structure of G1269A Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib

• DOI: 10.2210/pdb4ANQ/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): Yes 


• Deposited: 2012-03-21 Released: 2013-03-27 
• Deposition Author(s): McTigue, M., Deng, Y., Liu, W., Brooun, A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.76 Å
• R-Value Free: 0.217 
• R-Value Work: 0.201 

Literature

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Huang, Q., Johnson, T.W., Bailey, S., Brooun, A., Bunker, K.D., Burke, B.J., Collins, M.R., Cook, A.S., Cui, J.J., Dack, K.N., Deal, J.G., Deng, Y., Dinh, D., Engstrom, L.D., He, M., Hoffman, J., Hoffman, R.L., Johnson, P.S., Kania, R.S., Lam, H., Lam, J.L., Le, P.T., Li, Q., Lingardo, L., Liu, W., Lu, M.W., Mctigue, M., Palmer, C.L., Richardson, P.F., Sach, N.W., Shen, H., Smeal, T., Smith, G.L., Stewart, A.E., Timofeevski, S., Tsaparikos, K., Wang, H., Zhu, H., Zhu, J., Zou, H.Y., Edwards, M.P.

(2014) J Med Chem 57: 1170

• PubMed: 24432909 
• DOI: 10.1021/jm401805h
• Primary Citation of Related Structures:  
  2YFX, 2YHV, 4ANQ, 4ANL, 4CD0, 4CCB, 4CCU


• PubMed Abstract: 
  

Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).

---

Organizational Affiliation: 

La Jolla Laboratories, Pfizer Worldwide Research and Development , 10770 Science Center Drive, San Diego, California 92121, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
ALK TYROSINE KINASE RECEPTOR	A	342	Homo sapiens	Mutation(s): 1  Gene Names: ALK EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9UM73 (Homo sapiens) Explore Q9UM73  Go to UniProtKB:  Q9UM73
PHAROS:  Q9UM73 GTEx:  ENSG00000171094

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
VGH	B [auth A]	3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine C21 H22 Cl2 F N5 O KTEIFNKAUNYNJU-GFCCVEGCSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
VGH	IC50:  11   nM  BindingDB
VGH	IC50:  3039   nM  BindingDB
VGH	IC50:  5.5   nM  BindingDB
VGH	Ki:  8.199999809265137   nM  BindingDB
VGH	IC50:  1600   nM  BindingDB
VGH	EC50:  22840   nM  BindingDB
VGH	IC50:  1148   nM  BindingDB
VGH	IC50:  5   nM  BindingDB
VGH	IC50:  1.2000000476837158   nM  BindingDB
VGH	IC50:  972   nM  BindingDB
VGH	IC50:  1026   nM  BindingDB
VGH	IC50:  17.600000381469727   nM  BindingDB
VGH	IC50:  843   nM  BindingDB
VGH	IC50:  2.0999999046325684   nM  BindingDB
VGH	IC50:  600   nM  BindingDB
VGH	IC50:  605   nM  BindingDB
VGH	IC50:  626   nM  BindingDB
VGH	IC50:  1   nM  BindingDB
VGH	IC50:  478   nM  BindingDB
VGH	IC50:  353   nM  BindingDB
VGH	IC50:  355   nM  BindingDB
VGH	IC50:  337   nM  BindingDB
VGH	Kd:  3.299999952316284   nM  BindingDB
VGH	IC50:  220   nM  BindingDB
VGH	IC50:  17.299999237060547   nM  BindingDB
VGH	IC50:  188   nM  BindingDB
VGH	IC50:  200   nM  BindingDB
VGH	IC50:  148   nM  BindingDB
VGH	IC50:  151   nM  BindingDB
VGH	IC50:  165   nM  BindingDB
VGH	IC50:  2.700000047683716   nM  BindingDB
VGH	IC50:  605   nM  Binding MOAD
VGH	IC50:  133   nM  BindingDB
VGH	IC50:  110   nM  BindingDB
VGH	IC50:  2   nM  BindingDB
VGH	Kd:  3.5999999046325684   nM  BindingDB
VGH	IC50:  72   nM  BindingDB
VGH	IC50:  78   nM  BindingDB
VGH	IC50:  80   nM  BindingDB
VGH	IC50:  51   nM  BindingDB
VGH	EC50:  2042   nM  BindingDB
VGH	IC50:  55   nM  BindingDB
VGH	IC50:  56   nM  BindingDB
VGH	IC50:  7.400000095367432   nM  BindingDB
VGH	IC50:  36   nM  BindingDB
VGH	IC50:  7.670000076293945   nM  BindingDB
VGH	IC50:  0.6399999856948853   nM  BindingDB
VGH	Ki:  0.7400000095367432   nM  BindingDB
VGH	IC50:  32   nM  BindingDB
VGH	IC50:  28   nM  BindingDB
VGH	IC50:  2.9000000953674316   nM  BindingDB
VGH	IC50:  24   nM  BindingDB
VGH	IC50:  25   nM  BindingDB
VGH	IC50:  20   nM  BindingDB
VGH	IC50 :  605   nM  PDBBind
VGH	Kd:  4.400000095367432   nM  BindingDB
VGH	IC50:  14   nM  BindingDB
VGH	EC50:  575   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.76 Å
• R-Value Free: 0.217 
• R-Value Work: 0.201 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 51.626	α = 90
b = 57.473	β = 90
c = 104.617	γ = 90

Software Package:

Software Name	Purpose
CNX	refinement
AutoPROC	data reduction
SCALA	data scaling
CNX	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2012-03-21 
• Released Date: 2013-03-27 
Deposition Author(s): McTigue, M., Deng, Y., Liu, W., Brooun, A.

Revision History  

• Version 1.0: 2013-03-27
  Type: Initial release
  
• Version 1.1: 2014-03-19
  Changes: Atomic model, Database references
• Version 1.2: 2019-05-08
  Changes: Data collection, Experimental preparation, Other